FDA Accepts NPS Pharma's sNDA - Analyst Blog

By
A A A

NPS Pharmaceuticals, Inc. ( NPSP ) announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental new drug application (sNDA) on Gattex for review. The company is looking to expand the label to include data from the 2 year phase III STEPS 2 extension study (n=88). The FDA's decision regarding the label expansion should be out by Jun 28, 2014.

We note that Gattex, NPS Pharma's sole marketed product, is available in the U.S. since Feb 2013 for treating adults with short bowel syndrome (SBS), dependent on parenteral support. The drug was cleared in the EU in 2012 (European trade name: Revestive). The company expects to launch the drug in the EU in the first half of 2014.

We note that Gattex has proved to be effective for long-term use according to data from the STEPS 2 study. Data from the study, presented by NPS Pharma, at the American College of gastroenterology annual scientific meeting and postgraduate course earlier in the year revealed that Gattex treatment resulted in additional, clinically meaningful reductions in the volume and days/week of parenteral support requirements. Moreover, long-term Gattex treatment did not result in any new unexpected safety issues.

NPS Pharma is also developing Natpara (rhPTH [1-84]) for the treatment of adult hypoparathyroidism. The company submitted a Biologic License Application to the FDA for the drug last month.

NPS Pharma carries a Zacks Rank #3 (Hold). Companies such as Actelion Ltd. ( ALIOF ), Jazz Pharmaceuticals ( JAZZ ) and AMAG Pharmaceuticals, Inc. ( AMAG ) currently look attractive. All 3 stocks carry a Zacks Rank #1 (Strong Buy).



ACTELION LTD (ALIOF): Get Free Report

AMAG PHARMA INC (AMAG): Free Stock Analysis Report

JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report

NPS PHARMA INC (NPSP): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: ALIOF , AMAG , JAZZ , NPSP , SBS

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

118,436,464
  • $116.72 ▲ 6.95%
75,353,208
  • $15.34 ▼ 1.86%
60,152,759
  • $47.07 ▼ 1.92%
58,800,675
  • $41.755 ▼ 2.12%
50,248,081
  • $6.70 ▼ 10.07%
35,484,181
  • $32.80 ▼ 0.03%
33,775,700
  • $24.015 ▼ 1.50%
33,380,477
  • $98.41 ▼ 4.40%
As of 1/28/2015, 03:13 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com